<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00627926</url>
  </required_header>
  <id_info>
    <org_study_id>VX07-950-108</org_study_id>
    <nct_id>NCT00627926</nct_id>
  </id_info>
  <brief_title>A Phase 3 Study of Telaprevir in Combination With Pegasys® and Copegus® in Treatment-Naive Subjects With Genotype 1 Hepatitis C Virus (HCV)</brief_title>
  <official_title>A Phase 3 Study of 2 Dose Regimens of Telaprevir in Combination With Peginterferon Alfa-2a (Pegasys®) and Ribavirin (Copegus®) in Treatment-Naive Subjects With Genotype 1 Chronic Hepatitis C</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vertex Pharmaceuticals Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tibotec Pharmaceutical Limited</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Vertex Pharmaceuticals Incorporated</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 3 study to evaluate the efficacy and safety of two dosing regimens of telaprevir in
      combination with pegylated interferon alfa 2a (Peg-IFN-alfa-2a) and ribavirin (RBV).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects Achieving Sustained Viral Response (SVR), Demonstrated by Achieving Undetectable Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels 24 Weeks After Last Planned Dose of Study Treatment</measure>
    <time_frame>24 weeks after last planned dose of study treatment (up to Week 72)</time_frame>
    <description>The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The lower limit of quantification was 25 international units per milliliter (IU/mL) and the lower limit of detection was 10 IU/mL. Two results are reported: 1) Protocol defined SVR: undetectable HCV RNA at 24 weeks after the last planned dose of study treatment without any confirmed detectable HCV RNA between end of treatment visit (up to Week 48) and 24 weeks after last planned dose (up to Week 72); 2) SVR as per FDA guidance (snapshot analysis): undetectable HCV RNA at 24 weeks after the last planned dose of study treatment. Analysis was based only on the HCV RNA assessment in visit window (+/-2 weeks); if there were more than 1 assessment in the window, the last measurement was used.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Undetectable HCV RNA at Week 72</measure>
    <time_frame>Week 72 (24 weeks after last dose for subjects with a planned treatment duration of 48 weeks and 48 weeks after last dose for subjects with planned treatment duration of 24 weeks)</time_frame>
    <description>The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The lower limit of quantification was 25 IU/mL and the lower limit of detection was 10 IU/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Achieving Rapid Viral Response (RVR), Demonstrated by Achieving Undetectable HCV RNA 4 Weeks After Starting Study Treatment</measure>
    <time_frame>Week 4</time_frame>
    <description>The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The lower limit of quantification was 25 IU/mL and the lower limit of detection was 10 IU/mL. RVR was defined as undetectable HCV RNA 4 weeks after the start of study treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Achieving Extended Rapid Viral Response (eRVR), Demonstrated by Achieving Undetectable HCV RNA at Week 4 and at Week 12</measure>
    <time_frame>Week 4 and Week 12</time_frame>
    <description>The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The lower limit of quantification was 25 IU/mL and the lower limit of detection was 10 IU/mL. eRVR was defined as undetectable HCV RNA at both Week 4 and Week 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Undetectable HCV RNA at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The lower limit of quantification was 25 IU/mL and the lower limit of detection was 10 IU/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Undetectable HCV RNA at End of Treatment (EOT)</measure>
    <time_frame>End of treatment (up to Week 48)</time_frame>
    <description>The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The lower limit of quantification was 25 IU/mL and the lower limit of detection was 10 IU/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Undetectable HCV RNA 12 Weeks After Last Planned Dose of Study Treatment</measure>
    <time_frame>12 weeks after last planned dose of study treatment (up to Week 60)</time_frame>
    <description>The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The lower limit of quantification was 25 IU/mL and the lower limit of detection was 10 IU/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Undetectable HCV RNA 24 Weeks After Last Actual Dose of Study Treatment</measure>
    <time_frame>24 weeks after last actual dose of study treatment (up to Week 72)</time_frame>
    <description>The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The lower limit of quantification was 25 IU/mL and the lower limit of detection was 10 IU/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Viral Relapse Planned and Viral Relapse Actual</measure>
    <time_frame>After last dose of study drug up to 24 week antiviral follow-up (up to Week 72)</time_frame>
    <description>Viral relapse was defined as having detectable HCV RNA during antiviral follow-up. The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The lower limit of quantification was 25 IU/mL and the lower limit of detection was 10 IU/mL. For viral relapse, 2 analyses were performed: planned and actual. The planned analyses was measured from the end of treatment (EOT) visit to 24 weeks after the last planned dose of study treatment. The actual analyses was measured from the EOT visit to 24 weeks after the last actual dose of study treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemical Response: Number of Subjects With Grade 3 and 4 Shifts From Baseline in Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST) Levels</measure>
    <time_frame>Baseline up to Week 48</time_frame>
    <description>Criteria for grading severity (toxicity) of ALT and AST: Grade 0 (&lt;1.25*upper limit of normal [ULN]); Grade 1 (mild=1.25 to 2.5*ULN); Grade 2 (moderate=2.6 to 5.0*ULN); Grade 3 (severe= greater than 5.0 to 20.0*ULN); Grade 4 (life-threatening= greater than 20.0*ULN). Number of subjects with Grade 3 shift (from Grade 0, Grade 1 or Grade 2 baseline) and Grade 4 shift (from Grade 0, Grade 1, Grade 2 or Grade 3 baseline) are reported. If a subject experienced more than 1 severity grade shifts during post baseline assessments, the maximum severity grade shift was considered.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Noninvasive Markers of Fibrosis: Number of Subjects With Improvement in FibroTest Analysis</measure>
    <time_frame>Baseline through 24 weeks after last planned dose of study treatment (up to Week 72)</time_frame>
    <description>FibroTest analysis was a biomarker analysis test used to generate a score that was correlated with the degree of liver damage. The FibroTest score was calculated from the results of a six-parameter blood test, combining six serum markers (alpha-2-macroglobulin, haptoglobin, apolipoprotein A1, gamma-glutamyl transpeptidase, total bilirubin, and alanine transaminase). The FibroTest score (F score) may range from 0.00 (Grade F0) to 1.00 (Grade F4), where F0= no fibrosis and F4=cirrhosis. Results were presented separately for subjects who achieved SVR at 24 weeks after the last planned dose of study treatment and those who did not achieve SVR at 24 weeks after the last planned dose of study treatment. Improvement was defined as decrease of at least 1 grade relative to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatigue Severity Scale (FSS) Total Score</measure>
    <time_frame>Baseline, Week 4, 12, 24, 36, 48, 72</time_frame>
    <description>FSS was a 9-item questionnaire where each item was scored on a scale of 1 to 7 (higher scores indicated higher influence of fatigue). FSS total score was calculated as the average of individual items on the questionnaire and FSS total score ranged from 1 to 7, where higher score indicated higher influence of fatigue.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Adverse Events (AEs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>Baseline up to Week 48</time_frame>
    <description>AE: any adverse change from the subject's baseline (pre-treatment) condition, including any adverse experience, abnormal recording or clinical laboratory assessment value which occurs during the course of the study, whether it is considered related to the study drug or not. An adverse event includes any newly occurring event or previous condition that has increased in severity or frequency since the administration of study drug. SAE: medical event or condition, which falls into any of the following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, in-patient hospitalization/prolongation of hospitalization, persistent/significant disability or incapacity, congenital anomaly/birth defect, important medical event. &quot;Study drug&quot; includes all investigational agents (including placebo, if applicable) administered during the course of the study.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1095</enrollment>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>PBO 12 Week+Peg-IFN-alfa-2a, RBV 48 Week</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (PBO) matched to telaprevir 750 mg tablet thrice daily for 12 weeks in combination with pegylated interferon alfa 2a (Peg-IFN-alfa-2a) 180 microgram per week (mcg/week) subcutaneous injection and ribavirin (RBV) tablet orally twice daily at a dose of 1000 milligram per day (mg/day) for subjects weighing less than (&lt;) 75 kilogram (kg) and 1200 mg/day for subjects weighing greater than or equal to (&gt;=) 75 kg, for 48 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Telaprevir 8 Week, PBO 4 Week+Peg-IFN-alfa-2a, RBV 24/48 Week</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Telaprevir 750 mg tablet thrice daily for 8 weeks, then PBO matched to Telaprevir 750 mg tablet thrice daily for 4 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing &lt;75 kg and 1200 mg/day for subjects weighing &gt;=75 kg, for 24 to 48 weeks depending on individual response to telaprevir treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Telaprevir 12 Week+Peg-IFN-alfa-2a, RBV 24/48 Week</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Telaprevir 750 mg tablet thrice daily for 12 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing &lt;75 kg and 1200 mg/day for subjects weighing &gt;=75 kg, for 24 to 48 weeks depending on individual response to telaprevir treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pegylated Interferon Alfa 2a</intervention_name>
    <description>subcutaneous injection, 180 micrograms once per week</description>
    <arm_group_label>PBO 12 Week+Peg-IFN-alfa-2a, RBV 48 Week</arm_group_label>
    <arm_group_label>Telaprevir 8 Week, PBO 4 Week+Peg-IFN-alfa-2a, RBV 24/48 Week</arm_group_label>
    <arm_group_label>Telaprevir 12 Week+Peg-IFN-alfa-2a, RBV 24/48 Week</arm_group_label>
    <other_name>Pegasys, Peg-IFN-alfa-2a</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telaprevir</intervention_name>
    <description>375 mg tablets administered orally every 8 hours at a dose of 750 mg</description>
    <arm_group_label>Telaprevir 8 Week, PBO 4 Week+Peg-IFN-alfa-2a, RBV 24/48 Week</arm_group_label>
    <arm_group_label>Telaprevir 12 Week+Peg-IFN-alfa-2a, RBV 24/48 Week</arm_group_label>
    <other_name>VX-950</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin</intervention_name>
    <description>200 mg tablets administered orally twice daily at a dose of 1000 mg/day for subjects weighing &lt;75 kg and 1200 mg/day for subjects weighing ≥75 kg</description>
    <arm_group_label>PBO 12 Week+Peg-IFN-alfa-2a, RBV 48 Week</arm_group_label>
    <arm_group_label>Telaprevir 8 Week, PBO 4 Week+Peg-IFN-alfa-2a, RBV 24/48 Week</arm_group_label>
    <arm_group_label>Telaprevir 12 Week+Peg-IFN-alfa-2a, RBV 24/48 Week</arm_group_label>
    <other_name>Copegus, RBV</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Telaprevir matching placebo</description>
    <arm_group_label>PBO 12 Week+Peg-IFN-alfa-2a, RBV 48 Week</arm_group_label>
    <arm_group_label>Telaprevir 8 Week, PBO 4 Week+Peg-IFN-alfa-2a, RBV 24/48 Week</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Has not received any previous treatment with any approved or investigational drug or
             drug regimen for the treatment of hepatitis C

          -  Male and female subjects, 18 to 70 years of age, inclusive

          -  Genotype 1, chronic hepatitis C with detectable Hepatitis C Virus (HCV) Ribonucleic
             Acid (RNA)

          -  Screening laboratory values, tests, and physical exam within acceptable ranges

          -  Able and willing to follow contraception requirements

          -  Able to read and understand, and willing to sign the informed consent form and abide
             by the study restrictions

        Exclusion Criteria

          -  Subject has any contraindications to Pegasys® or Copegus® therapy

          -  Evidence of hepatic decompensation in cirrhotic subjects

          -  History of organ transplant

          -  History of, or any current medical condition which could impact the safety of the
             subject in participation in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Vertex Pharmaceuticals Incorporated</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93721</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>LaJolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90822</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92154</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34243</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>South Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Carmel</city>
        <state>Indiana</state>
        <zip>46032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Portland</city>
        <state>Maine</state>
        <zip>04102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Laurel</city>
        <state>Maryland</state>
        <zip>20707</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St Louis</city>
        <state>Missouri</state>
        <zip>63104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <zip>11030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York City</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York City</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York City</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York City</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Valhalla</city>
        <state>New York</state>
        <zip>10595</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fayetteville</city>
        <state>North Carolina</state>
        <zip>28304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cincinatti</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Annandale</city>
        <state>Virginia</state>
        <zip>22003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23249</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Darlinghurst</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fitzroy</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Greenslopes</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Melbourne</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Perth</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Westmead</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Woolloongabba</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Linz</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Calgary</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toronto</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vancouver</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Winnipeg</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Clichy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Creteil</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pessac</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bochum</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dusseldorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Freiburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Koln</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Muenchen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nazareth</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Petah Tikva</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tel Hashomer</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bialystok</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Czeladz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kielce</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lodz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wroclaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santurce</city>
        <zip>00909</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hampstead</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Austria</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Puerto Rico</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 22, 2008</study_first_submitted>
  <study_first_submitted_qc>February 22, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 4, 2008</study_first_posted>
  <results_first_submitted>June 22, 2011</results_first_submitted>
  <results_first_submitted_qc>June 22, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 21, 2011</results_first_posted>
  <last_update_submitted>July 16, 2014</last_update_submitted>
  <last_update_submitted_qc>July 16, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 8, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Genotype 1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>A total of 1095 subjects were enrolled, of which 7 subjects discontinued the study prior to study drug administration. A total of 1088 subjects started treatment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>PBO 12 Week+Peg-IFN-alfa-2a, RBV 48 Week</title>
          <description>Placebo (PBO) matched to telaprevir 750 mg tablet thrice daily for 12 weeks in combination with pegylated interferon alfa 2a (Peg-IFN-alfa-2a) 180 microgram per week (mcg/week) subcutaneous injection and ribavirin (RBV) tablet orally twice daily at a dose of 1000 milligram per day (mg/day) for subjects weighing less than (&lt;) 75 kilogram (kg) and 1200 mg/day for subjects weighing greater than or equal to (&gt;=) 75 kg, for 48 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Telaprevir 8 Week, PBO 4 Week+Peg-IFN-alfa-2a, RBV 24/48 Week</title>
          <description>Telaprevir 750 mg tablet thrice daily for 8 weeks, then PBO matched to Telaprevir 750 mg tablet thrice daily for 4 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing &lt;75 kg and 1200 mg/day for subjects weighing &gt;=75 kg, for 24 to 48 weeks depending on individual response to telaprevir treatment.</description>
        </group>
        <group group_id="P3">
          <title>Telaprevir 12 Week+Peg-IFN-alfa-2a, RBV 24/48 Week</title>
          <description>Telaprevir 750 mg tablet thrice daily for 12 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing &lt;75 kg and 1200 mg/day for subjects weighing &gt;=75 kg, for 24 to 48 weeks depending on individual response to telaprevir treatment.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="361"/>
                <participants group_id="P2" count="364"/>
                <participants group_id="P3" count="363"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="202"/>
                <participants group_id="P2" count="260"/>
                <participants group_id="P3" count="268"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="159"/>
                <participants group_id="P2" count="104"/>
                <participants group_id="P3" count="95"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="37"/>
                <participants group_id="P3" count="36"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="118"/>
                <participants group_id="P2" count="40"/>
                <participants group_id="P3" count="38"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Noncompliance/unspecified</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="23"/>
                <participants group_id="P3" count="17"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The full analysis (FA) set included all randomized subjects who received at least 1 dose of any study drug.</population>
      <group_list>
        <group group_id="B1">
          <title>PBO 12 Week+Peg-IFN-alfa-2a, RBV 48 Week</title>
          <description>Placebo (PBO) matched to telaprevir 750 mg tablet thrice daily for 12 weeks in combination with pegylated interferon alfa 2a (Peg-IFN-alfa-2a) 180 microgram per week (mcg/week) subcutaneous injection and ribavirin (RBV) tablet orally twice daily at a dose of 1000 milligram per day (mg/day) for subjects weighing less than (&lt;) 75 kilogram (kg) and 1200 mg/day for subjects weighing greater than or equal to (&gt;=) 75 kg, for 48 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Telaprevir 8 Week, PBO 4 Week+Peg-IFN-alfa-2a, RBV 24/48 Week</title>
          <description>Telaprevir 750 mg tablet thrice daily for 8 weeks, then PBO matched to Telaprevir 750 mg tablet thrice daily for 4 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing &lt;75 kg and 1200 mg/day for subjects weighing &gt;=75 kg, for 24 to 48 weeks depending on individual response to telaprevir treatment.</description>
        </group>
        <group group_id="B3">
          <title>Telaprevir 12 Week+Peg-IFN-alfa-2a, RBV 24/48 Week</title>
          <description>Telaprevir 750 mg tablet thrice daily for 12 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing &lt;75 kg and 1200 mg/day for subjects weighing &gt;=75 kg, for 24 to 48 weeks depending on individual response to telaprevir treatment.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="361"/>
            <count group_id="B2" value="364"/>
            <count group_id="B3" value="363"/>
            <count group_id="B4" value="1088"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="357"/>
                    <measurement group_id="B2" value="359"/>
                    <measurement group_id="B3" value="353"/>
                    <measurement group_id="B4" value="1069"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.8" spread="10.0"/>
                    <measurement group_id="B2" value="47.0" spread="10.9"/>
                    <measurement group_id="B3" value="46.5" spread="10.8"/>
                    <measurement group_id="B4" value="46.8" spread="10.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="150"/>
                    <measurement group_id="B2" value="153"/>
                    <measurement group_id="B3" value="149"/>
                    <measurement group_id="B4" value="452"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="211"/>
                    <measurement group_id="B2" value="211"/>
                    <measurement group_id="B3" value="214"/>
                    <measurement group_id="B4" value="636"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>North America</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="214"/>
                    <measurement group_id="B2" value="227"/>
                    <measurement group_id="B3" value="214"/>
                    <measurement group_id="B4" value="655"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Europe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="106"/>
                    <measurement group_id="B2" value="100"/>
                    <measurement group_id="B3" value="104"/>
                    <measurement group_id="B4" value="310"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Argentina</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Israel</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Undetectable HCV RNA at Week 72</title>
        <description>The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The lower limit of quantification was 25 IU/mL and the lower limit of detection was 10 IU/mL.</description>
        <time_frame>Week 72 (24 weeks after last dose for subjects with a planned treatment duration of 48 weeks and 48 weeks after last dose for subjects with planned treatment duration of 24 weeks)</time_frame>
        <population>The FA set included all randomized subjects who received at least 1 dose of any study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>PBO 12 Week+Peg-IFN-alfa-2a, RBV 48 Week</title>
            <description>Placebo (PBO) matched to telaprevir 750 mg tablet thrice daily for 12 weeks in combination with pegylated interferon alfa 2a (Peg-IFN-alfa-2a) 180 microgram per week (mcg/week) subcutaneous injection and ribavirin (RBV) tablet orally twice daily at a dose of 1000 milligram per day (mg/day) for subjects weighing less than (&lt;) 75 kilogram (kg) and 1200 mg/day for subjects weighing greater than or equal to (&gt;=) 75 kg, for 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Telaprevir 8 Week, PBO 4 Week+Peg-IFN-alfa-2a, RBV 24/48 Week</title>
            <description>Telaprevir 750 mg tablet thrice daily for 8 weeks, then PBO matched to Telaprevir 750 mg tablet thrice daily for 4 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing &lt;75 kg and 1200 mg/day for subjects weighing &gt;=75 kg, for 24 to 48 weeks depending on individual response to telaprevir treatment.</description>
          </group>
          <group group_id="O3">
            <title>Telaprevir 12 Week+Peg-IFN-alfa-2a, RBV 24/48 Week</title>
            <description>Telaprevir 750 mg tablet thrice daily for 12 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing &lt;75 kg and 1200 mg/day for subjects weighing &gt;=75 kg, for 24 to 48 weeks depending on individual response to telaprevir treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Undetectable HCV RNA at Week 72</title>
          <description>The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The lower limit of quantification was 25 IU/mL and the lower limit of detection was 10 IU/mL.</description>
          <population>The FA set included all randomized subjects who received at least 1 dose of any study drug.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="361"/>
                <count group_id="O2" value="364"/>
                <count group_id="O3" value="363"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="158"/>
                    <measurement group_id="O2" value="243"/>
                    <measurement group_id="O3" value="265"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in percentage</param_type>
            <param_value>23.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>15.9</ci_lower_limit>
            <ci_upper_limit>30.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in percentage</param_type>
            <param_value>29.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>22.4</ci_lower_limit>
            <ci_upper_limit>36.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Achieving Rapid Viral Response (RVR), Demonstrated by Achieving Undetectable HCV RNA 4 Weeks After Starting Study Treatment</title>
        <description>The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The lower limit of quantification was 25 IU/mL and the lower limit of detection was 10 IU/mL. RVR was defined as undetectable HCV RNA 4 weeks after the start of study treatment.</description>
        <time_frame>Week 4</time_frame>
        <population>The FA set included all randomized subjects who received at least 1 dose of any study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>PBO 12 Week+Peg-IFN-alfa-2a, RBV 48 Week</title>
            <description>Placebo (PBO) matched to telaprevir 750 mg tablet thrice daily for 12 weeks in combination with pegylated interferon alfa 2a (Peg-IFN-alfa-2a) 180 microgram per week (mcg/week) subcutaneous injection and ribavirin (RBV) tablet orally twice daily at a dose of 1000 milligram per day (mg/day) for subjects weighing less than (&lt;) 75 kilogram (kg) and 1200 mg/day for subjects weighing greater than or equal to (&gt;=) 75 kg, for 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Telaprevir 8 Week, PBO 4 Week+Peg-IFN-alfa-2a, RBV 24/48 Week</title>
            <description>Telaprevir 750 mg tablet thrice daily for 8 weeks, then PBO matched to Telaprevir 750 mg tablet thrice daily for 4 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing &lt;75 kg and 1200 mg/day for subjects weighing &gt;=75 kg, for 24 to 48 weeks depending on individual response to telaprevir treatment.</description>
          </group>
          <group group_id="O3">
            <title>Telaprevir 12 Week+Peg-IFN-alfa-2a, RBV 24/48 Week</title>
            <description>Telaprevir 750 mg tablet thrice daily for 12 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing &lt;75 kg and 1200 mg/day for subjects weighing &gt;=75 kg, for 24 to 48 weeks depending on individual response to telaprevir treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Achieving Rapid Viral Response (RVR), Demonstrated by Achieving Undetectable HCV RNA 4 Weeks After Starting Study Treatment</title>
          <description>The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The lower limit of quantification was 25 IU/mL and the lower limit of detection was 10 IU/mL. RVR was defined as undetectable HCV RNA 4 weeks after the start of study treatment.</description>
          <population>The FA set included all randomized subjects who received at least 1 dose of any study drug.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="361"/>
                <count group_id="O2" value="364"/>
                <count group_id="O3" value="363"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="242"/>
                    <measurement group_id="O3" value="246"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in percentage</param_type>
            <param_value>57.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>51.4</ci_lower_limit>
            <ci_upper_limit>62.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in percentage</param_type>
            <param_value>58.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>52.7</ci_lower_limit>
            <ci_upper_limit>64.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Achieving Extended Rapid Viral Response (eRVR), Demonstrated by Achieving Undetectable HCV RNA at Week 4 and at Week 12</title>
        <description>The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The lower limit of quantification was 25 IU/mL and the lower limit of detection was 10 IU/mL. eRVR was defined as undetectable HCV RNA at both Week 4 and Week 12.</description>
        <time_frame>Week 4 and Week 12</time_frame>
        <population>The FA set included all randomized subjects who received at least 1 dose of any study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>PBO 12 Week+Peg-IFN-alfa-2a, RBV 48 Week</title>
            <description>Placebo (PBO) matched to telaprevir 750 mg tablet thrice daily for 12 weeks in combination with pegylated interferon alfa 2a (Peg-IFN-alfa-2a) 180 microgram per week (mcg/week) subcutaneous injection and ribavirin (RBV) tablet orally twice daily at a dose of 1000 milligram per day (mg/day) for subjects weighing less than (&lt;) 75 kilogram (kg) and 1200 mg/day for subjects weighing greater than or equal to (&gt;=) 75 kg, for 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Telaprevir 8 Week, PBO 4 Week+Peg-IFN-alfa-2a, RBV 24/48 Week</title>
            <description>Telaprevir 750 mg tablet thrice daily for 8 weeks, then PBO matched to Telaprevir 750 mg tablet thrice daily for 4 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing &lt;75 kg and 1200 mg/day for subjects weighing &gt;=75 kg, for 24 to 48 weeks depending on individual response to telaprevir treatment.</description>
          </group>
          <group group_id="O3">
            <title>Telaprevir 12 Week+Peg-IFN-alfa-2a, RBV 24/48 Week</title>
            <description>Telaprevir 750 mg tablet thrice daily for 12 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing &lt;75 kg and 1200 mg/day for subjects weighing &gt;=75 kg, for 24 to 48 weeks depending on individual response to telaprevir treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Achieving Extended Rapid Viral Response (eRVR), Demonstrated by Achieving Undetectable HCV RNA at Week 4 and at Week 12</title>
          <description>The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The lower limit of quantification was 25 IU/mL and the lower limit of detection was 10 IU/mL. eRVR was defined as undetectable HCV RNA at both Week 4 and Week 12.</description>
          <population>The FA set included all randomized subjects who received at least 1 dose of any study drug.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="361"/>
                <count group_id="O2" value="364"/>
                <count group_id="O3" value="363"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="207"/>
                    <measurement group_id="O3" value="212"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in percentage</param_type>
            <param_value>48.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>43.0</ci_lower_limit>
            <ci_upper_limit>54.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in percentage</param_type>
            <param_value>50.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>44.6</ci_lower_limit>
            <ci_upper_limit>56.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Undetectable HCV RNA at Week 12</title>
        <description>The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The lower limit of quantification was 25 IU/mL and the lower limit of detection was 10 IU/mL.</description>
        <time_frame>Week 12</time_frame>
        <population>The FA set included all randomized subjects who received at least 1 dose of any study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>PBO 12 Week+Peg-IFN-alfa-2a, RBV 48 Week</title>
            <description>Placebo (PBO) matched to telaprevir 750 mg tablet thrice daily for 12 weeks in combination with pegylated interferon alfa 2a (Peg-IFN-alfa-2a) 180 microgram per week (mcg/week) subcutaneous injection and ribavirin (RBV) tablet orally twice daily at a dose of 1000 milligram per day (mg/day) for subjects weighing less than (&lt;) 75 kilogram (kg) and 1200 mg/day for subjects weighing greater than or equal to (&gt;=) 75 kg, for 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Telaprevir 8 Week, PBO 4 Week+Peg-IFN-alfa-2a, RBV 24/48 Week</title>
            <description>Telaprevir 750 mg tablet thrice daily for 8 weeks, then PBO matched to Telaprevir 750 mg tablet thrice daily for 4 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing &lt;75 kg and 1200 mg/day for subjects weighing &gt;=75 kg, for 24 to 48 weeks depending on individual response to telaprevir treatment.</description>
          </group>
          <group group_id="O3">
            <title>Telaprevir 12 Week+Peg-IFN-alfa-2a, RBV 24/48 Week</title>
            <description>Telaprevir 750 mg tablet thrice daily for 12 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing &lt;75 kg and 1200 mg/day for subjects weighing &gt;=75 kg, for 24 to 48 weeks depending on individual response to telaprevir treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Undetectable HCV RNA at Week 12</title>
          <description>The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The lower limit of quantification was 25 IU/mL and the lower limit of detection was 10 IU/mL.</description>
          <population>The FA set included all randomized subjects who received at least 1 dose of any study drug.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="361"/>
                <count group_id="O2" value="364"/>
                <count group_id="O3" value="363"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="146"/>
                    <measurement group_id="O2" value="277"/>
                    <measurement group_id="O3" value="283"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in percentage</param_type>
            <param_value>35.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>29.0</ci_lower_limit>
            <ci_upper_limit>42.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in percentage</param_type>
            <param_value>37.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>30.9</ci_lower_limit>
            <ci_upper_limit>44.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Undetectable HCV RNA at End of Treatment (EOT)</title>
        <description>The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The lower limit of quantification was 25 IU/mL and the lower limit of detection was 10 IU/mL.</description>
        <time_frame>End of treatment (up to Week 48)</time_frame>
        <population>The FA set included all randomized subjects who received at least 1 dose of any study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>PBO 12 Week+Peg-IFN-alfa-2a, RBV 48 Week</title>
            <description>Placebo (PBO) matched to telaprevir 750 mg tablet thrice daily for 12 weeks in combination with pegylated interferon alfa 2a (Peg-IFN-alfa-2a) 180 microgram per week (mcg/week) subcutaneous injection and ribavirin (RBV) tablet orally twice daily at a dose of 1000 milligram per day (mg/day) for subjects weighing less than (&lt;) 75 kilogram (kg) and 1200 mg/day for subjects weighing greater than or equal to (&gt;=) 75 kg, for 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Telaprevir 8 Week, PBO 4 Week+Peg-IFN-alfa-2a, RBV 24/48 Week</title>
            <description>Telaprevir 750 mg tablet thrice daily for 8 weeks, then PBO matched to Telaprevir 750 mg tablet thrice daily for 4 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing &lt;75 kg and 1200 mg/day for subjects weighing &gt;=75 kg, for 24 to 48 weeks depending on individual response to telaprevir treatment.</description>
          </group>
          <group group_id="O3">
            <title>Telaprevir 12 Week+Peg-IFN-alfa-2a, RBV 24/48 Week</title>
            <description>Telaprevir 750 mg tablet thrice daily for 12 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing &lt;75 kg and 1200 mg/day for subjects weighing &gt;=75 kg, for 24 to 48 weeks depending on individual response to telaprevir treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Undetectable HCV RNA at End of Treatment (EOT)</title>
          <description>The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The lower limit of quantification was 25 IU/mL and the lower limit of detection was 10 IU/mL.</description>
          <population>The FA set included all randomized subjects who received at least 1 dose of any study drug.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="361"/>
                <count group_id="O2" value="364"/>
                <count group_id="O3" value="363"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="229"/>
                    <measurement group_id="O2" value="295"/>
                    <measurement group_id="O3" value="314"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in percentage</param_type>
            <param_value>17.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>11.2</ci_lower_limit>
            <ci_upper_limit>24.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in percentage</param_type>
            <param_value>23.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>17.0</ci_lower_limit>
            <ci_upper_limit>29.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Undetectable HCV RNA 12 Weeks After Last Planned Dose of Study Treatment</title>
        <description>The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The lower limit of quantification was 25 IU/mL and the lower limit of detection was 10 IU/mL.</description>
        <time_frame>12 weeks after last planned dose of study treatment (up to Week 60)</time_frame>
        <population>The FA set included all randomized subjects who received at least 1 dose of any study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>PBO 12 Week+Peg-IFN-alfa-2a, RBV 48 Week</title>
            <description>Placebo (PBO) matched to telaprevir 750 mg tablet thrice daily for 12 weeks in combination with pegylated interferon alfa 2a (Peg-IFN-alfa-2a) 180 microgram per week (mcg/week) subcutaneous injection and ribavirin (RBV) tablet orally twice daily at a dose of 1000 milligram per day (mg/day) for subjects weighing less than (&lt;) 75 kilogram (kg) and 1200 mg/day for subjects weighing greater than or equal to (&gt;=) 75 kg, for 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Telaprevir 8 Week, PBO 4 Week+Peg-IFN-alfa-2a, RBV 24/48 Week</title>
            <description>Telaprevir 750 mg tablet thrice daily for 8 weeks, then PBO matched to Telaprevir 750 mg tablet thrice daily for 4 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing &lt;75 kg and 1200 mg/day for subjects weighing &gt;=75 kg, for 24 to 48 weeks depending on individual response to telaprevir treatment.</description>
          </group>
          <group group_id="O3">
            <title>Telaprevir 12 Week+Peg-IFN-alfa-2a, RBV 24/48 Week</title>
            <description>Telaprevir 750 mg tablet thrice daily for 12 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing &lt;75 kg and 1200 mg/day for subjects weighing &gt;=75 kg, for 24 to 48 weeks depending on individual response to telaprevir treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Undetectable HCV RNA 12 Weeks After Last Planned Dose of Study Treatment</title>
          <description>The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The lower limit of quantification was 25 IU/mL and the lower limit of detection was 10 IU/mL.</description>
          <population>The FA set included all randomized subjects who received at least 1 dose of any study drug.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="361"/>
                <count group_id="O2" value="364"/>
                <count group_id="O3" value="363"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="161"/>
                    <measurement group_id="O2" value="255"/>
                    <measurement group_id="O3" value="275"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in percentage</param_type>
            <param_value>25.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>18.5</ci_lower_limit>
            <ci_upper_limit>32.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in percentage</param_type>
            <param_value>31.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>24.4</ci_lower_limit>
            <ci_upper_limit>37.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Undetectable HCV RNA 24 Weeks After Last Actual Dose of Study Treatment</title>
        <description>The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The lower limit of quantification was 25 IU/mL and the lower limit of detection was 10 IU/mL.</description>
        <time_frame>24 weeks after last actual dose of study treatment (up to Week 72)</time_frame>
        <population>The FA set included all randomized subjects who received at least 1 dose of any study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>PBO 12 Week+Peg-IFN-alfa-2a, RBV 48 Week</title>
            <description>Placebo (PBO) matched to telaprevir 750 mg tablet thrice daily for 12 weeks in combination with pegylated interferon alfa 2a (Peg-IFN-alfa-2a) 180 microgram per week (mcg/week) subcutaneous injection and ribavirin (RBV) tablet orally twice daily at a dose of 1000 milligram per day (mg/day) for subjects weighing less than (&lt;) 75 kilogram (kg) and 1200 mg/day for subjects weighing greater than or equal to (&gt;=) 75 kg, for 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Telaprevir 8 Week, PBO 4 Week+Peg-IFN-alfa-2a, RBV 24/48 Week</title>
            <description>Telaprevir 750 mg tablet thrice daily for 8 weeks, then PBO matched to Telaprevir 750 mg tablet thrice daily for 4 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing &lt;75 kg and 1200 mg/day for subjects weighing &gt;=75 kg, for 24 to 48 weeks depending on individual response to telaprevir treatment.</description>
          </group>
          <group group_id="O3">
            <title>Telaprevir 12 Week+Peg-IFN-alfa-2a, RBV 24/48 Week</title>
            <description>Telaprevir 750 mg tablet thrice daily for 12 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing &lt;75 kg and 1200 mg/day for subjects weighing &gt;=75 kg, for 24 to 48 weeks depending on individual response to telaprevir treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Undetectable HCV RNA 24 Weeks After Last Actual Dose of Study Treatment</title>
          <description>The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The lower limit of quantification was 25 IU/mL and the lower limit of detection was 10 IU/mL.</description>
          <population>The FA set included all randomized subjects who received at least 1 dose of any study drug.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="361"/>
                <count group_id="O2" value="364"/>
                <count group_id="O3" value="363"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="158"/>
                    <measurement group_id="O2" value="251"/>
                    <measurement group_id="O3" value="274"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in percentage</param_type>
            <param_value>25.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>18.2</ci_lower_limit>
            <ci_upper_limit>32.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in percentage</param_type>
            <param_value>31.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>24.9</ci_lower_limit>
            <ci_upper_limit>38.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Viral Relapse Planned and Viral Relapse Actual</title>
        <description>Viral relapse was defined as having detectable HCV RNA during antiviral follow-up. The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The lower limit of quantification was 25 IU/mL and the lower limit of detection was 10 IU/mL. For viral relapse, 2 analyses were performed: planned and actual. The planned analyses was measured from the end of treatment (EOT) visit to 24 weeks after the last planned dose of study treatment. The actual analyses was measured from the EOT visit to 24 weeks after the last actual dose of study treatment.</description>
        <time_frame>After last dose of study drug up to 24 week antiviral follow-up (up to Week 72)</time_frame>
        <population>Analysis population included subjects who completed their assigned study drug treatment and had undetectable HCV RNA at the completion of treatment (up to Week 48).</population>
        <group_list>
          <group group_id="O1">
            <title>PBO 12 Week+Peg-IFN-alfa-2a, RBV 48 Week</title>
            <description>Placebo (PBO) matched to telaprevir 750 mg tablet thrice daily for 12 weeks in combination with pegylated interferon alfa 2a (Peg-IFN-alfa-2a) 180 microgram per week (mcg/week) subcutaneous injection and ribavirin (RBV) tablet orally twice daily at a dose of 1000 milligram per day (mg/day) for subjects weighing less than (&lt;) 75 kilogram (kg) and 1200 mg/day for subjects weighing greater than or equal to (&gt;=) 75 kg, for 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Telaprevir 8 Week, PBO 4 Week+Peg-IFN-alfa-2a, RBV 24/48 Week</title>
            <description>Telaprevir 750 mg tablet thrice daily for 8 weeks, then PBO matched to Telaprevir 750 mg tablet thrice daily for 4 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing &lt;75 kg and 1200 mg/day for subjects weighing &gt;=75 kg, for 24 to 48 weeks depending on individual response to telaprevir treatment.</description>
          </group>
          <group group_id="O3">
            <title>Telaprevir 12 Week+Peg-IFN-alfa-2a, RBV 24/48 Week</title>
            <description>Telaprevir 750 mg tablet thrice daily for 12 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing &lt;75 kg and 1200 mg/day for subjects weighing &gt;=75 kg, for 24 to 48 weeks depending on individual response to telaprevir treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Viral Relapse Planned and Viral Relapse Actual</title>
          <description>Viral relapse was defined as having detectable HCV RNA during antiviral follow-up. The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The lower limit of quantification was 25 IU/mL and the lower limit of detection was 10 IU/mL. For viral relapse, 2 analyses were performed: planned and actual. The planned analyses was measured from the end of treatment (EOT) visit to 24 weeks after the last planned dose of study treatment. The actual analyses was measured from the EOT visit to 24 weeks after the last actual dose of study treatment.</description>
          <population>Analysis population included subjects who completed their assigned study drug treatment and had undetectable HCV RNA at the completion of treatment (up to Week 48).</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="229"/>
                <count group_id="O2" value="295"/>
                <count group_id="O3" value="314"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Viral Relapse Planned</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Viral Relapse Actual</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Biochemical Response: Number of Subjects With Grade 3 and 4 Shifts From Baseline in Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST) Levels</title>
        <description>Criteria for grading severity (toxicity) of ALT and AST: Grade 0 (&lt;1.25*upper limit of normal [ULN]); Grade 1 (mild=1.25 to 2.5*ULN); Grade 2 (moderate=2.6 to 5.0*ULN); Grade 3 (severe= greater than 5.0 to 20.0*ULN); Grade 4 (life-threatening= greater than 20.0*ULN). Number of subjects with Grade 3 shift (from Grade 0, Grade 1 or Grade 2 baseline) and Grade 4 shift (from Grade 0, Grade 1, Grade 2 or Grade 3 baseline) are reported. If a subject experienced more than 1 severity grade shifts during post baseline assessments, the maximum severity grade shift was considered.</description>
        <time_frame>Baseline up to Week 48</time_frame>
        <population>The FA set included all randomized subjects who received at least 1 dose of any study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>PBO 12 Week+Peg-IFN-alfa-2a, RBV 48 Week</title>
            <description>Placebo (PBO) matched to telaprevir 750 mg tablet thrice daily for 12 weeks in combination with pegylated interferon alfa 2a (Peg-IFN-alfa-2a) 180 microgram per week (mcg/week) subcutaneous injection and ribavirin (RBV) tablet orally twice daily at a dose of 1000 milligram per day (mg/day) for subjects weighing less than (&lt;) 75 kilogram (kg) and 1200 mg/day for subjects weighing greater than or equal to (&gt;=) 75 kg, for 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Telaprevir 8 Week, PBO 4 Week+Peg-IFN-alfa-2a, RBV 24/48 Week</title>
            <description>Telaprevir 750 mg tablet thrice daily for 8 weeks, then PBO matched to Telaprevir 750 mg tablet thrice daily for 4 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing &lt;75 kg and 1200 mg/day for subjects weighing &gt;=75 kg, for 24 to 48 weeks depending on individual response to telaprevir treatment.</description>
          </group>
          <group group_id="O3">
            <title>Telaprevir 12 Week+Peg-IFN-alfa-2a, RBV 24/48 Week</title>
            <description>Telaprevir 750 mg tablet thrice daily for 12 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing &lt;75 kg and 1200 mg/day for subjects weighing &gt;=75 kg, for 24 to 48 weeks depending on individual response to telaprevir treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Biochemical Response: Number of Subjects With Grade 3 and 4 Shifts From Baseline in Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST) Levels</title>
          <description>Criteria for grading severity (toxicity) of ALT and AST: Grade 0 (&lt;1.25*upper limit of normal [ULN]); Grade 1 (mild=1.25 to 2.5*ULN); Grade 2 (moderate=2.6 to 5.0*ULN); Grade 3 (severe= greater than 5.0 to 20.0*ULN); Grade 4 (life-threatening= greater than 20.0*ULN). Number of subjects with Grade 3 shift (from Grade 0, Grade 1 or Grade 2 baseline) and Grade 4 shift (from Grade 0, Grade 1, Grade 2 or Grade 3 baseline) are reported. If a subject experienced more than 1 severity grade shifts during post baseline assessments, the maximum severity grade shift was considered.</description>
          <population>The FA set included all randomized subjects who received at least 1 dose of any study drug.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="361"/>
                <count group_id="O2" value="364"/>
                <count group_id="O3" value="363"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ALT Grade 3 toxicity grade shift</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT Grade 4 toxicity grade shift</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST Grade 3 toxicity grade shift</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST Grade 4 toxicity grade shift</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Noninvasive Markers of Fibrosis: Number of Subjects With Improvement in FibroTest Analysis</title>
        <description>FibroTest analysis was a biomarker analysis test used to generate a score that was correlated with the degree of liver damage. The FibroTest score was calculated from the results of a six-parameter blood test, combining six serum markers (alpha-2-macroglobulin, haptoglobin, apolipoprotein A1, gamma-glutamyl transpeptidase, total bilirubin, and alanine transaminase). The FibroTest score (F score) may range from 0.00 (Grade F0) to 1.00 (Grade F4), where F0= no fibrosis and F4=cirrhosis. Results were presented separately for subjects who achieved SVR at 24 weeks after the last planned dose of study treatment and those who did not achieve SVR at 24 weeks after the last planned dose of study treatment. Improvement was defined as decrease of at least 1 grade relative to baseline.</description>
        <time_frame>Baseline through 24 weeks after last planned dose of study treatment (up to Week 72)</time_frame>
        <population>The FA set included all randomized subjects who received at least 1 dose of any study drug. Here &quot;number of participants analyzed&quot; signifies those subjects who were evaluable for FibroTest Analysis and &quot;n&quot; signifies those subjects who were evaluable for FibroTest Analysis in specified category for each treatment arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>PBO 12 Week+Peg-IFN-alfa-2a, RBV 48 Week</title>
            <description>Placebo (PBO) matched to telaprevir 750 mg tablet thrice daily for 12 weeks in combination with pegylated interferon alfa 2a (Peg-IFN-alfa-2a) 180 microgram per week (mcg/week) subcutaneous injection and ribavirin (RBV) tablet orally twice daily at a dose of 1000 milligram per day (mg/day) for subjects weighing less than (&lt;) 75 kilogram (kg) and 1200 mg/day for subjects weighing greater than or equal to (&gt;=) 75 kg, for 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Telaprevir 8 Week, PBO 4 Week+Peg-IFN-alfa-2a, RBV 24/48 Week</title>
            <description>Telaprevir 750 mg tablet thrice daily for 8 weeks, then PBO matched to Telaprevir 750 mg tablet thrice daily for 4 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing &lt;75 kg and 1200 mg/day for subjects weighing &gt;=75 kg, for 24 to 48 weeks depending on individual response to telaprevir treatment.</description>
          </group>
          <group group_id="O3">
            <title>Telaprevir 12 Week+Peg-IFN-alfa-2a, RBV 24/48 Week</title>
            <description>Telaprevir 750 mg tablet thrice daily for 12 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing &lt;75 kg and 1200 mg/day for subjects weighing &gt;=75 kg, for 24 to 48 weeks depending on individual response to telaprevir treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Noninvasive Markers of Fibrosis: Number of Subjects With Improvement in FibroTest Analysis</title>
          <description>FibroTest analysis was a biomarker analysis test used to generate a score that was correlated with the degree of liver damage. The FibroTest score was calculated from the results of a six-parameter blood test, combining six serum markers (alpha-2-macroglobulin, haptoglobin, apolipoprotein A1, gamma-glutamyl transpeptidase, total bilirubin, and alanine transaminase). The FibroTest score (F score) may range from 0.00 (Grade F0) to 1.00 (Grade F4), where F0= no fibrosis and F4=cirrhosis. Results were presented separately for subjects who achieved SVR at 24 weeks after the last planned dose of study treatment and those who did not achieve SVR at 24 weeks after the last planned dose of study treatment. Improvement was defined as decrease of at least 1 grade relative to baseline.</description>
          <population>The FA set included all randomized subjects who received at least 1 dose of any study drug. Here &quot;number of participants analyzed&quot; signifies those subjects who were evaluable for FibroTest Analysis and &quot;n&quot; signifies those subjects who were evaluable for FibroTest Analysis in specified category for each treatment arm, respectively.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="273"/>
                <count group_id="O2" value="233"/>
                <count group_id="O3" value="261"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SVR achieved (136, 180, 214)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="59"/>
                    <measurement group_id="O3" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SVR not achieved (137, 53, 47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fatigue Severity Scale (FSS) Total Score</title>
        <description>FSS was a 9-item questionnaire where each item was scored on a scale of 1 to 7 (higher scores indicated higher influence of fatigue). FSS total score was calculated as the average of individual items on the questionnaire and FSS total score ranged from 1 to 7, where higher score indicated higher influence of fatigue.</description>
        <time_frame>Baseline, Week 4, 12, 24, 36, 48, 72</time_frame>
        <population>The FA set included all randomized subjects who received at least 1 dose of any study drug. Here &quot;n&quot; signifies those participants who were evaluable for this measure at given time points for each group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>PBO 12 Week+Peg-IFN-alfa-2a, RBV 48 Week</title>
            <description>Placebo (PBO) matched to telaprevir 750 mg tablet thrice daily for 12 weeks in combination with pegylated interferon alfa 2a (Peg-IFN-alfa-2a) 180 microgram per week (mcg/week) subcutaneous injection and ribavirin (RBV) tablet orally twice daily at a dose of 1000 milligram per day (mg/day) for subjects weighing less than (&lt;) 75 kilogram (kg) and 1200 mg/day for subjects weighing greater than or equal to (&gt;=) 75 kg, for 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Telaprevir 8 Week, PBO 4 Week+Peg-IFN-alfa-2a, RBV 24/48 Week</title>
            <description>Telaprevir 750 mg tablet thrice daily for 8 weeks, then PBO matched to Telaprevir 750 mg tablet thrice daily for 4 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing &lt;75 kg and 1200 mg/day for subjects weighing &gt;=75 kg, for 24 to 48 weeks depending on individual response to telaprevir treatment.</description>
          </group>
          <group group_id="O3">
            <title>Telaprevir 12 Week+Peg-IFN-alfa-2a, RBV 24/48 Week</title>
            <description>Telaprevir 750 mg tablet thrice daily for 12 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing &lt;75 kg and 1200 mg/day for subjects weighing &gt;=75 kg, for 24 to 48 weeks depending on individual response to telaprevir treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Fatigue Severity Scale (FSS) Total Score</title>
          <description>FSS was a 9-item questionnaire where each item was scored on a scale of 1 to 7 (higher scores indicated higher influence of fatigue). FSS total score was calculated as the average of individual items on the questionnaire and FSS total score ranged from 1 to 7, where higher score indicated higher influence of fatigue.</description>
          <population>The FA set included all randomized subjects who received at least 1 dose of any study drug. Here &quot;n&quot; signifies those participants who were evaluable for this measure at given time points for each group, respectively.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="361"/>
                <count group_id="O2" value="364"/>
                <count group_id="O3" value="363"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=343, 351, 346)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" spread="1.66"/>
                    <measurement group_id="O2" value="3.2" spread="1.63"/>
                    <measurement group_id="O3" value="3.0" spread="1.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=334, 326, 329)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1" spread="1.74"/>
                    <measurement group_id="O2" value="4.4" spread="1.74"/>
                    <measurement group_id="O3" value="4.5" spread="1.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=329, 310, 312)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4" spread="1.69"/>
                    <measurement group_id="O2" value="4.4" spread="1.68"/>
                    <measurement group_id="O3" value="4.8" spread="1.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (n=317, 307, 304)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3" spread="1.73"/>
                    <measurement group_id="O2" value="4.3" spread="1.71"/>
                    <measurement group_id="O3" value="4.3" spread="1.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36 (n=296, 282, 297)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1" spread="1.80"/>
                    <measurement group_id="O2" value="3.4" spread="1.84"/>
                    <measurement group_id="O3" value="3.3" spread="1.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48 (n=286, 282, 294)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" spread="1.82"/>
                    <measurement group_id="O2" value="3.0" spread="1.75"/>
                    <measurement group_id="O3" value="3.1" spread="1.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72 (n=296, 270, 289)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" spread="1.77"/>
                    <measurement group_id="O2" value="2.6" spread="1.56"/>
                    <measurement group_id="O3" value="2.6" spread="1.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Achieving Sustained Viral Response (SVR), Demonstrated by Achieving Undetectable Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels 24 Weeks After Last Planned Dose of Study Treatment</title>
        <description>The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The lower limit of quantification was 25 international units per milliliter (IU/mL) and the lower limit of detection was 10 IU/mL. Two results are reported: 1) Protocol defined SVR: undetectable HCV RNA at 24 weeks after the last planned dose of study treatment without any confirmed detectable HCV RNA between end of treatment visit (up to Week 48) and 24 weeks after last planned dose (up to Week 72); 2) SVR as per FDA guidance (snapshot analysis): undetectable HCV RNA at 24 weeks after the last planned dose of study treatment. Analysis was based only on the HCV RNA assessment in visit window (+/-2 weeks); if there were more than 1 assessment in the window, the last measurement was used.</description>
        <time_frame>24 weeks after last planned dose of study treatment (up to Week 72)</time_frame>
        <population>The full analysis (FA) set included all randomized subjects who received at least 1 dose of any study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>PBO 12 Week+Peg-IFN-alfa-2a, RBV 48 Week</title>
            <description>Placebo (PBO) matched to telaprevir 750 mg tablet thrice daily for 12 weeks in combination with pegylated interferon alfa 2a (Peg-IFN-alfa-2a) 180 microgram per week (mcg/week) subcutaneous injection and ribavirin (RBV) tablet orally twice daily at a dose of 1000 milligram per day (mg/day) for subjects weighing less than (&lt;) 75 kilogram (kg) and 1200 mg/day for subjects weighing greater than or equal to (&gt;=) 75 kg, for 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Telaprevir 8 Week, PBO 4 Week+Peg-IFN-alfa-2a, RBV 24/48 Week</title>
            <description>Telaprevir 750 mg tablet thrice daily for 8 weeks, then PBO matched to Telaprevir 750 mg tablet thrice daily for 4 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing &lt;75 kg and 1200 mg/day for subjects weighing &gt;=75 kg, for 24 to 48 weeks depending on individual response to telaprevir treatment.</description>
          </group>
          <group group_id="O3">
            <title>Telaprevir 12 Week+Peg-IFN-alfa-2a, RBV 24/48 Week</title>
            <description>Telaprevir 750 mg tablet thrice daily for 12 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing &lt;75 kg and 1200 mg/day for subjects weighing &gt;=75 kg, for 24 to 48 weeks depending on individual response to telaprevir treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Achieving Sustained Viral Response (SVR), Demonstrated by Achieving Undetectable Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels 24 Weeks After Last Planned Dose of Study Treatment</title>
          <description>The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The lower limit of quantification was 25 international units per milliliter (IU/mL) and the lower limit of detection was 10 IU/mL. Two results are reported: 1) Protocol defined SVR: undetectable HCV RNA at 24 weeks after the last planned dose of study treatment without any confirmed detectable HCV RNA between end of treatment visit (up to Week 48) and 24 weeks after last planned dose (up to Week 72); 2) SVR as per FDA guidance (snapshot analysis): undetectable HCV RNA at 24 weeks after the last planned dose of study treatment. Analysis was based only on the HCV RNA assessment in visit window (+/-2 weeks); if there were more than 1 assessment in the window, the last measurement was used.</description>
          <population>The full analysis (FA) set included all randomized subjects who received at least 1 dose of any study drug.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="361"/>
                <count group_id="O2" value="364"/>
                <count group_id="O3" value="363"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SVR: Protocol Defined</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="158"/>
                    <measurement group_id="O2" value="250"/>
                    <measurement group_id="O3" value="271"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SVR: FDA Guidance</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="166"/>
                    <measurement group_id="O2" value="261"/>
                    <measurement group_id="O3" value="285"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>SVR Protocol Defined: undetectable HCV RNA at 24 weeks after the last planned dose of study treatment without any confirmed detectable HCV RNA between end of treatment visit (up to Week 48) and 24 weeks after last planned dose (up to Week 72).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in percentage</param_type>
            <param_value>24.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>17.9</ci_lower_limit>
            <ci_upper_limit>31.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>SVR Protocol Defined: undetectable HCV RNA at 24 weeks after the last planned dose of study treatment without any confirmed detectable HCV RNA between end of treatment visit (up to Week 48) and 24 weeks after last planned dose (up to Week 72).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in percentage</param_type>
            <param_value>30.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>24.1</ci_lower_limit>
            <ci_upper_limit>37.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>SVR FDA Guidance: undetectable HCV RNA at 24 weeks after the last planned dose of study treatment. Analysis was based only on the HCV RNA assessment in visit window (+/-2 weeks); if there were more than 1 assessment in the window, the last measurement was used.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in percentage</param_type>
            <param_value>25.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>18.8</ci_lower_limit>
            <ci_upper_limit>32.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>SVR FDA Guidance: undetectable HCV RNA at 24 weeks after the last planned dose of study treatment. Analysis was based only on the HCV RNA assessment in visit window (+/-2 weeks); if there were more than 1 assessment in the window, the last measurement was used.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in percentage</param_type>
            <param_value>32.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>25.9</ci_lower_limit>
            <ci_upper_limit>39.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Adverse Events (AEs) and Serious Adverse Events (SAEs)</title>
        <description>AE: any adverse change from the subject's baseline (pre-treatment) condition, including any adverse experience, abnormal recording or clinical laboratory assessment value which occurs during the course of the study, whether it is considered related to the study drug or not. An adverse event includes any newly occurring event or previous condition that has increased in severity or frequency since the administration of study drug. SAE: medical event or condition, which falls into any of the following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, in-patient hospitalization/prolongation of hospitalization, persistent/significant disability or incapacity, congenital anomaly/birth defect, important medical event. &quot;Study drug&quot; includes all investigational agents (including placebo, if applicable) administered during the course of the study.</description>
        <time_frame>Baseline up to Week 48</time_frame>
        <population>The FA set included all randomized subjects who received at least 1 dose of any study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>PBO 12 Week+Peg-IFN-alfa-2a, RBV 48 Week</title>
            <description>Placebo (PBO) matched to telaprevir 750 mg tablet thrice daily for 12 weeks in combination with pegylated interferon alfa 2a (Peg-IFN-alfa-2a) 180 microgram per week (mcg/week) subcutaneous injection and ribavirin (RBV) tablet orally twice daily at a dose of 1000 milligram per day (mg/day) for subjects weighing less than (&lt;) 75 kilogram (kg) and 1200 mg/day for subjects weighing greater than or equal to (&gt;=) 75 kg, for 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Telaprevir 8 Week, PBO 4 Week+Peg-IFN-alfa-2a, RBV 24/48 Week</title>
            <description>Telaprevir 750 mg tablet thrice daily for 8 weeks, then PBO matched to Telaprevir 750 mg tablet thrice daily for 4 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing &lt;75 kg and 1200 mg/day for subjects weighing &gt;=75 kg, for 24 to 48 weeks depending on individual response to telaprevir treatment.</description>
          </group>
          <group group_id="O3">
            <title>Telaprevir 12 Week+Peg-IFN-alfa-2a, RBV 24/48 Week</title>
            <description>Telaprevir 750 mg tablet thrice daily for 12 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing &lt;75 kg and 1200 mg/day for subjects weighing &gt;=75 kg, for 24 to 48 weeks depending on individual response to telaprevir treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Adverse Events (AEs) and Serious Adverse Events (SAEs)</title>
          <description>AE: any adverse change from the subject's baseline (pre-treatment) condition, including any adverse experience, abnormal recording or clinical laboratory assessment value which occurs during the course of the study, whether it is considered related to the study drug or not. An adverse event includes any newly occurring event or previous condition that has increased in severity or frequency since the administration of study drug. SAE: medical event or condition, which falls into any of the following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, in-patient hospitalization/prolongation of hospitalization, persistent/significant disability or incapacity, congenital anomaly/birth defect, important medical event. &quot;Study drug&quot; includes all investigational agents (including placebo, if applicable) administered during the course of the study.</description>
          <population>The FA set included all randomized subjects who received at least 1 dose of any study drug.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="361"/>
                <count group_id="O2" value="364"/>
                <count group_id="O3" value="363"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="354"/>
                    <measurement group_id="O2" value="362"/>
                    <measurement group_id="O3" value="361"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="31"/>
                    <measurement group_id="O3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>AEs and SAEs During Dosing From Baseline to Week 48</time_frame>
      <desc>In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (&quot;number of affected participants&quot;) of both adverse event tables.</desc>
      <group_list>
        <group group_id="E1">
          <title>PBO 12 Week+Peg-IFN-alfa-2a, RBV 48 Week</title>
          <description>Placebo (PBO) matched to telaprevir 750 mg tablet thrice daily for 12 weeks in combination with pegylated interferon alfa 2a (Peg-IFN-alfa-2a) 180 microgram per week (mcg/week) subcutaneous injection and ribavirin (RBV) tablet orally twice daily at a dose of 1000 milligram per day (mg/day) for subjects weighing less than (&lt;) 75 kilogram (kg) and 1200 mg/day for subjects weighing greater than or equal to (&gt;=) 75 kg, for 48 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Telaprevir 8 Week, PBO 4 Week+Peg-IFN-alfa-2a, RBV 24/48 Week</title>
          <description>Telaprevir 750 mg tablet thrice daily for 8 weeks, then PBO matched to Telaprevir 750 mg tablet thrice daily for 4 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing &lt;75 kg and 1200 mg/day for subjects weighing &gt;=75 kg, for 24 to 48 weeks depending on individual response to telaprevir treatment.</description>
        </group>
        <group group_id="E3">
          <title>Telaprevir 12 Week+Peg-IFN-alfa-2a, RBV 24/48 Week</title>
          <description>Telaprevir 750 mg tablet thrice daily for 12 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing &lt;75 kg and 1200 mg/day for subjects weighing &gt;=75 kg, for 24 to 48 weeks depending on individual response to telaprevir treatment.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="364"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="363"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>anemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="364"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="364"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>anemia haemolytic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="364"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="364"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="364"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="364"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="363"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="364"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="364"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>palpitations</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="364"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="363"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>urachal abnormality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="364"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="363"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>retinal exudates</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="364"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>retinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="364"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="364"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="363"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="364"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>anal fistula</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="364"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>colitis ischaemic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="364"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="364"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>diverticular perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="364"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="364"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>internal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="364"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>intestinal ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="364"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="364"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="364"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>salivary gland calculus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="364"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="363"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="364"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="364"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="363"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="364"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="364"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>hepatic cirrhosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="364"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>hepatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="364"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="363"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>cryoglobulinaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="364"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="363"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="364"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="364"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="364"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>lobar pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="364"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="364"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="364"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="364"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>abscess limb</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="364"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>acute sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="364"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="364"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>cellulitis staphylococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="364"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>escherichia bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="364"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="364"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="364"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>lung abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="364"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>lymphangitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="364"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>perirectal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="364"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="364"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>staphylococcal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="364"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>staphylococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="364"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>subcutaneous abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="364"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="364"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="363"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>thermal burn</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="364"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="363"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="364"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="364"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="363"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="364"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>costochondritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="364"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>intervertebral disc</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="364"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="364"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>rheumatoid arthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="364"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="363"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="364"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>convulsion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="364"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>migraine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="364"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>altered state of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="364"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>global amnesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="364"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="363"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="364"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>completed suicide</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="364"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="364"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>insomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="364"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>panic attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="364"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>psychotic disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="364"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="363"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="364"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="364"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="364"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="363"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>metrorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="364"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="363"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="364"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="363"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="364"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="364"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>eczema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="364"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>leukocytoclastic vasculitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="364"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>rash maculo-papular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="364"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>stevens-johnson syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="364"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="363"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="364"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>phlebitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="364"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>thrombophlebitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="364"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="363"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="354" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="362" subjects_at_risk="364"/>
                <counts group_id="E3" subjects_affected="361" subjects_at_risk="363"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>anaemia</sub_title>
                <counts group_id="E1" subjects_affected="70" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="141" subjects_at_risk="364"/>
                <counts group_id="E3" subjects_affected="135" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="68" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="62" subjects_at_risk="364"/>
                <counts group_id="E3" subjects_affected="51" subjects_at_risk="363"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="364"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="363"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" subjects_affected="112" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="146" subjects_at_risk="364"/>
                <counts group_id="E3" subjects_affected="156" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="80" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="115" subjects_at_risk="364"/>
                <counts group_id="E3" subjects_affected="102" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>vomiting</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="55" subjects_at_risk="364"/>
                <counts group_id="E3" subjects_affected="55" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="364"/>
                <counts group_id="E3" subjects_affected="43" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>anorectal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="364"/>
                <counts group_id="E3" subjects_affected="46" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="364"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="364"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>constipation</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="364"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>anal pruritus</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="364"/>
                <counts group_id="E3" subjects_affected="31" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="364"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="364"/>
                <counts group_id="E3" subjects_affected="31" subjects_at_risk="363"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" subjects_affected="206" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="211" subjects_at_risk="364"/>
                <counts group_id="E3" subjects_affected="207" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="101" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="105" subjects_at_risk="364"/>
                <counts group_id="E3" subjects_affected="102" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="87" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="108" subjects_at_risk="364"/>
                <counts group_id="E3" subjects_affected="95" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>irritability</sub_title>
                <counts group_id="E1" subjects_affected="64" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="68" subjects_at_risk="364"/>
                <counts group_id="E3" subjects_affected="80" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>asthenia</sub_title>
                <counts group_id="E1" subjects_affected="58" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="62" subjects_at_risk="364"/>
                <counts group_id="E3" subjects_affected="56" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>chills</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="65" subjects_at_risk="364"/>
                <counts group_id="E3" subjects_affected="46" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>injection site erythema</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="364"/>
                <counts group_id="E3" subjects_affected="38" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>pain</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="364"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="363"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="364"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="364"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="363"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="364"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="363"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>anorexia</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="55" subjects_at_risk="364"/>
                <counts group_id="E3" subjects_affected="53" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="364"/>
                <counts group_id="E3" subjects_affected="36" subjects_at_risk="363"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>myalgia</sub_title>
                <counts group_id="E1" subjects_affected="77" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="76" subjects_at_risk="364"/>
                <counts group_id="E3" subjects_affected="54" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="68" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="56" subjects_at_risk="364"/>
                <counts group_id="E3" subjects_affected="49" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>back pain</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="364"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="364"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="363"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" subjects_affected="142" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="156" subjects_at_risk="364"/>
                <counts group_id="E3" subjects_affected="148" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>dizziness</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="50" subjects_at_risk="364"/>
                <counts group_id="E3" subjects_affected="57" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>distrubance in attention</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="364"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="364"/>
                <counts group_id="E3" subjects_affected="34" subjects_at_risk="363"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>insomnia</sub_title>
                <counts group_id="E1" subjects_affected="111" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="116" subjects_at_risk="364"/>
                <counts group_id="E3" subjects_affected="117" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>depression</sub_title>
                <counts group_id="E1" subjects_affected="79" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="61" subjects_at_risk="364"/>
                <counts group_id="E3" subjects_affected="66" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>anxiety</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="364"/>
                <counts group_id="E3" subjects_affected="35" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>affect lability</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="364"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="363"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>cough</sub_title>
                <counts group_id="E1" subjects_affected="86" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="76" subjects_at_risk="364"/>
                <counts group_id="E3" subjects_affected="61" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="52" subjects_at_risk="364"/>
                <counts group_id="E3" subjects_affected="47" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>dyspnoea exertional</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="364"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>pharyngolaryngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="364"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="363"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>pruritus</sub_title>
                <counts group_id="E1" subjects_affected="131" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="165" subjects_at_risk="364"/>
                <counts group_id="E3" subjects_affected="181" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>rash</sub_title>
                <counts group_id="E1" subjects_affected="88" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="129" subjects_at_risk="364"/>
                <counts group_id="E3" subjects_affected="133" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>alopecia</sub_title>
                <counts group_id="E1" subjects_affected="73" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="81" subjects_at_risk="364"/>
                <counts group_id="E3" subjects_affected="83" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>dry skin</sub_title>
                <counts group_id="E1" subjects_affected="66" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="66" subjects_at_risk="364"/>
                <counts group_id="E3" subjects_affected="63" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>rash papular</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="364"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>pruritus generalised</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="364"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>rash erythematous</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="364"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>rash pruritic</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="364"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>eczema</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="364"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="363"/>
              </event>
              <event>
                <sub_title>rash maculo-papular</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="364"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="363"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jeff Chodakewitz, M.D.</name_or_title>
      <organization>Vertex Pharmaceuticals Incorporated</organization>
      <phone>617-341-6777</phone>
      <email>Jeff_Chodakewitz@vrtx.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

